China’s National Medical Products Administration granted approval to Innovent Biologics’ ipilimumab (Tabosun) in combination with sintilimab for neoadjuvant treatment of resectable MSI‑high/mismatch repair‑deficient colon cancer and accepted Hutchmed’s NDA for fanregratinib with priority review. Innovent’s clearance marks a domestic CTLA‑4 win and adds a neoadjuvant option to the oncology toolkit in China. Hutchmed’s NMPA acceptance moves HMPL‑453 closer to becoming an FGFR‑targeted therapy in intrahepatic cholangiocarcinoma. Together, the actions show the NMPA’s continued prioritization of oncology approvals and could accelerate regional clinical development and commercialization timelines.